Genitourinary (GU) Masterclass 2025

Seoul, South Korea

11-12 July 2025

Meeting Chairs:

Dr Niara Oliveira,

Australia

Professor Daniel Petrylak,

United States

Professor Inkeun Park,

South Korea

Dr Alejo Rodriguez Vida,

Spain

Professor Sang Joon Shin,

South Korea

Thank you for your active participation during the recent Astellas-sponsored Asia-Pacific GU Masterclass. Here you will find short videos that showcase the meeting highlights from some of our faculty, as well as the slide content from all sessions.

Prescribing Information

Prescribing Information is available for PADCEV® (enfortumab vedotin) 20mg (here) and 30mg (here) and XTANDI® soft capsule 40mg (enzalutamide) here. This promotional meeting is fully sponsored and supported by Astellas, including speaker-related honoraria and production of materials. It is intended for healthcare professionals only.

PADCEV indications:

EV as first-line therapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer. Combination therapy with pembrolizumab.
EV as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 or programmed death-ligand 1 inhibitor, and have received a platinum-containing chemotherapy

XTANDI indications:

Treatment of patients with mCRPC with asymptomatic or mild symptoms
Treatment of patients with mCRPC previously treated with docetaxel
Treatment of patients with high-risk nmCRPC
Combined with ADT in the treatment of patients with mHSPC
Treatment of patients with high-risk BCR nmHSPC

Please refer to the Korean PI for PADCEV® (enfortumab vedotin) via the following QR Code:

PADCEV 20mg

PADCEV 30mg

Please refer to the Korean PI for XTANDI® (enzalutamide) via the following QR Code:

XTANDI soft capsule 40mg

AE reporting information

For Korea, healthcare professionals are asked to report any suspected adverse reactions to Astellas Pharma Korea. Inc
(Address: 7F Parnas tower, 521, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea; Telephone: +82 10 5254 3389; Email: safety-kr@kr.astellas.com)

1L, first line; 2L, second line; ADT, androgen deprivation therapy; AE, adverse event; BCR, biochemical recurrence; EV, enfortumab vedotin; GU, genitourinary; LA/mUC, locally advanced/metastatic urothelial carcinoma; mHSPC, metastatic hormone-sensitive prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; nmCRPC, non-metastatic hormone-sensitive prostate cancer.